Health
Israel’s Oramed Says Oral Insulin Capsule Trial a Success
Jan 30 (Reuters) – Oramed, an Israeli developer of oral drug delivery systems, said on Thursday a mid-stage trial for its oral insulin capsule for the treatment of type 2 diabetes met all primary and secondary endpoints.
During the Phase 2a trial, conducted under a U.S. Food and Drug Administration new drug protocol, 30 patients with type 2 diabetes took part in an in-patient setting for one week.
Endpoints of safety as well as pharmacodynamic and pharmacokinetic effects were evaluated.
